Figure 1.

(A) Adjusted odds (95% CI) of ≥10% weight gain by relevant parameters and (B) change in BMI category in the DTG/3TC and TAF-based regimen groups (post hoc analyses). BMI, body mass index; DTG, dolutegravir; INSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAF, tenofovir alafenamide; 3TC, lamivudine. ^aOdds ratios are presented in relation to the reference variable; the number of participants included in final model with covariate data at baseline and weight data at baseline and week 144. ^bOther races included American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, mixed White race, and multiple races. ^cOdds ratios and 95% CIs were calculated with a logistic regression model adjusting for treatment, race, sex, baseline CD4+ cell count (continuous), age (continuous), baseline weight (continuous), baseline third agent class, and prior TAF duration (continuous). ^dIn the TAF-based regimen group, 1 (<1%) participant with obesity at baseline had a normal BMI at week 144, and 1 (<1%) participant with a normal BMI had obesity at week 144.